Benjamin D, Aderka D, Livni E, Joshua H, Shaklai M, Pinkhas J
J Natl Cancer Inst. 1979 Nov;63(5):1175-7.
Migration inhibition factor (MIF) activity, expressed as a migration index, was studied in the sera of 48 chronic lymphatic leukemia (CLL) patients and 48 healthy controls. MIF activity was detected in the sera of 50% of the CLL patients. The medical condition of patients in advanced clinical stages (III and IV) and with detectable MIF activity was more stable (after 18-mo follow-up) than was that of the patients in advanced stages but without detectable MIF activity. No relationship was found between the clinical stage of the disease, absolute lymphocyte count, and MIF activity.
以迁移指数表示的迁移抑制因子（MIF）活性在48例慢性淋巴细胞白血病（CLL）患者和48例健康对照者的血清中进行了研究。在50%的CLL患者血清中检测到MIF活性。临床晚期（III期和IV期）且具有可检测到的MIF活性的患者的病情（经过18个月随访）比晚期但无可检测到的MIF活性的患者更稳定。未发现疾病临床分期、绝对淋巴细胞计数与MIF活性之间存在关联。
